Telix is a commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (‘theranostic’) radiopharmaceuticals. Telix’s extensive pipeline for urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning is ...

Telix is a commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (‘theranostic’) radiopharmaceuticals. Telix’s extensive pipeline for urologic oncology, neuro-oncology, musculoskeletal oncology and hematology is underpinned by a strong global supply, manufacturing and ...

Our core product pipeline, focused on urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning has generated extensive clinical data that demonstrate the potential for efficacy and good safety profile.

Telix Adds Lead-212 Isotope Production Capability. News, Telix today announces that it has developed and validated a breakthrough generator technology for the production of lead-212 (212Pb) and successfully completed first… Read more

1994年8月1日 · Telix 1.00 for Windows is a powerful telecommunications program that supports over 260 modems, multiple scripting languages, and RIPscrip graphics. Telix for Windows is a complete re-write based on the original DOS Telix software.

2012年9月4日 · Fast, powerful, and easy to use. 12 file transfer protocols, 200 + modem setups, terminal emulation, dialing directory, 2 powerful script languages,...

Telix Pharmaceuticals的研发管线旨在解决前列腺癌、肾癌（肾癌）、脑癌（ 胶质母细胞瘤 ）和血液系统癌症（骨髓调节）以及一系列免疫和罕见疾病中未满足的重大医疗需求。 01 前列腺癌

"Telix is now a global radiopharmaceutical company with a specialist commercial organization, a deep pipeline of late-stage and next-generation theranostic programs, and global manufacturing capabilities.

2021年4月25日 · Telix is a telecommunications program for Microsoft Windows developed and released in 1994

2020年11月1日 · Telix是一家专注于RDC的生物技术公司，总部位于澳大利亚墨尔本，聚焦新型放射性核素-靶向分子药物偶联技术，并利用这一创新技术平台开展RDC在癌症治疗、诊断领域的开发及应用。